Reply to: Prostate‐specific membrane antigen‐ PET ‐defined oligoprogressive castration‐resistant prostate cancer: is metastasis‐directed therapy ready for prime time?
- 26 October 2026
- journal article
- Published by Wiley in BJU International
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Ablative radiotherapy in castration‐resistant prostate cancerBJU International, 2026
- [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialThe Lancet Oncology, 2024
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Journal of Clinical Oncology, 2016